Showing 6471-6480 of 9943 results for "".
- Almirall's Seysara Now Availablehttps://practicaldermatology.com/news/seysara-now-available/2459932/SeysaraTM (sarecycline), a novel tetracycline-derived oral antibiotic developed specifically for the treatment of acne, is now commercially available from Almirall. Seysara™ was approved in October by FDA for the treatment of moderate to severe non-nodular inflammatory acne
- RealSelf Survey: 36 Percent of US Adults Are Considering Cosmetic Treatmentshttps://practicaldermatology.com/news/realself-36-percent-of-us-adults-are-considering-cosmetic-treatments/2459933/More than four in five U.S. adults want to improve their personal well-being or appearance in 2019, and 36 percent are considering cosmetic treatments, according to new RealSelf survey. Fully 82 percent of U.S. adults plan to make changes related to their personal well-being and/or appear
- Study: States with Fewer Melanoma Diagnoses Have Higher Death Rateshttps://practicaldermatology.com/news/study-states-with-fewer-melanoma-diagnoses-have-higher-death-rates/2459937/States with fewer melanoma diagnoses actually have higher death rates, report researchers at University of Utah Health. The researchers conducted a state-by-state analysis to understand the geographic disparities for patients diagnosed with melanoma. They found lower survival is associate
- New Review Highlights Comprehensive Treatment Guidelines for Severe ADhttps://practicaldermatology.com/news/new-review-highlights-comprehensive-treatment-guidelines-for-severe-ad/2459936/A team of investigators from the University of Colorado College of Nursing at CU Anschutz Medical Campus and National Jewish Health has identified comprehensive guidelines for managing severe atopic dermatitis (AD). The
- Peak Health Launches Plant-Based Regenerative Skincare Linehttps://practicaldermatology.com/news/peak-health-launches-plant-based-regenerative-skincare-line/2459940/Peak Health, launched Curere, a patented, regenerative skin care line created to treat a range of skin conditions, including acne, third-degree burns and necrosis. The line is made from all-natural ingredients to penetrate the dermal layer of skin and activate stem cells while also facili
- “Outstanding Clearance Rates” for Sebaceous Hyperplasia Facial Lesions Seen with NPShttps://practicaldermatology.com/news/outstanding-clearance-rates-for-sebaceous-hyperplasia-facial-lesions-seen-with-nps/2459943/Pulse Biosciences' Nano-Pulse Stimulation (NPS) technology achieved “outstanding clearance rates” on sebaceous hyperplasia lesions on the face, the company reports. Initial data indicate that 221 of 222 (99.5 percent
- JAK Kinase Inhibitors Show Promise in Treating Alopeciahttps://practicaldermatology.com/news/jak-kinase-inhibitors-show-promise-in-treating-alopecia/2459947/UPDATED -- New research suggests selective oral JAK kinase inhibitors may play a role in treating moderate-to-severe alopecia areata (AA). The findings were presented at the Inflammatory Skin Disease Summit in Vienna, Austria. In this
- Suneva Grows Their Aesthetics Portfolio with New Dealshttps://practicaldermatology.com/news/suneva-grows-their-aesthetics-portfolio-with-new-deals/2459946/Suneva® Medical, Inc., is partnering with Healeon Medical, Inc and Puregraft, LLC to add two new products to their a
- Bristol-Myers Squibb to Acquire Celgenehttps://practicaldermatology.com/news/bristol-myers-squibb-to-acquire-celgene/2459948/Bristol-Myers Squibb Company will acquire Celgene Corp. in a cash and stock transaction with an equity value of approximately $74 billion. The combined company with complementary areas of focus, will opera
- Dermavant Sciences Appoints Dr. Philip M. Brown as Chief Medical Officerhttps://practicaldermatology.com/news/dermavant-sciences-appoints-dr-philip-m-brown-as-chief-medical-officer/2459949/Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, appointed Philip M. Brown, MD, JD, as Chief Medical Officer. With more than 25 years of experience leading clinical development programs, Dr. Brown most recently served as head of global pharmaceutical drug development at G